Training Specialists in Cancer Care
The Fellowship Program in Hematology/Oncology
The Future of Cancer Research and Treatment

As a medical professional and specialist, you understand well the importance of training the next generation of hematologists and oncologists. You know that medical fellows improve the quality of patient care at the hospitals in which they practice; and you know that the University of Colorado Denver is the only training ground for medical oncologists and hematologists in our state.

Through the training of young fellows, senior faculty members perform at their highest level. Through the art of teaching, which involves the process of continually being challenged, thinking critically and collaborating with other talented physicians, mentoring clinicians reinforce their medical skills and become even better physicians.

The top-notch training of the next generation of hematology/oncology fellows is critical. Future hematologists and oncologists will need to be skilled in molecular diagnostics, management of biologic response modifiers and personalized medicine approaches that are now entering everyday practice. This infusion of new talent into our community comes at an exciting time when we are on the cusp of so many breakthroughs in cancer detection and treatment.

The training of cancer specialists is so important right now because of the rising incidence of cancer in our society. As the baby boom generation ages, medicine is making dramatic breakthroughs in heart disease and diabetes, to the point where these diseases are now considered chronic and people are living longer. Advancements have been made in cancer detection and treatment, and the longer people live, the more likely it is they will be diagnosed with cancer. And of course, as more people get cancer, the more oncologists we’ll require.

A study commissioned by the American Society of Clinical Oncology (ASCO) projects a significant shortage of medical and gynecologic oncologists in the United States by 2020. The study found that an aging and growing population, an increasing number of cancer survivors and slower growth in the supply of oncologists will result in a shortage of 2,550 to 4,080 oncologists by 2020.

The Hematology/Oncology Fellowship Program at the University of Colorado Denver will help ensure that we will have enough medical oncologists to care for the growing number of individuals with cancer in our society.

The Only Training Ground of its Kind in the Region

The Hematology/Oncology Fellowship Program at the University of Colorado Denver is an academically-oriented, three-year training program designed to produce outstanding hematologists and oncologists who have a lifelong commitment to scholarship, research and state-of-the-art patient care.
The Need

The cost to train hematologists and oncologists has risen dramatically in the past ten years. It is more expensive than ever to train fellows, including the increasing costs of health-care benefits, running a research lab, providing malpractice insurance and more. And it is increasingly difficult to attract the top medical minds into academia because of the huge debts incurred during their medical training and the fact that oncologists make a larger salary in private practice.

Thirty years ago when the fellowship program began, it enjoyed the support of University of Colorado Denver School of Medicine–affiliated hospitals, NIH training grants and individual faculty contributions from grant funds.

In today’s challenging economic times, grant funding is drying up, and our affiliated hospitals lack the funds to support the program at the level it requires.

The future of the Hematology/Oncology Fellowships depends on the generosity of individuals like you who have an insider's knowledge about the importance of specialty training and medical education.

“*Our three-year program attracts the best young doctors from across the nation and brings them to Colorado—where most of them stay—ultimately increasing the pool of talent and skilled caregivers for our state.*”

---

Endowed Funds at the CU Foundation

An endowment is a permanent fund established for a specific purpose—whether for a faculty member, scholarship, fellowship or general program support.

An endowed fund is invested and the distributions support the program for which the endowment was established. Endowed funds are invested for both income and growth.

You can establish an endowment with cash, securities, real estate or through an irrevocable bequest.

You Can Make a Difference

Join other insightful donors who have already stepped up to support a vibrant and healthy fellowship program. In order to keep it strong today and for the future, we are raising $5 million to endow fellowships in the area of Hematology/Oncology.

Your gift to create endowed fellowships will ensure that the training program will help create the next generation of specialists and advance the state of cancer research and care in Colorado, the nation and around the world.

Whether fellows stay in the Denver metro area or go to another institution, the Hematology/Oncology Fellowship Program makes an important contribution to the common good. Fellowships enable our specialists to share their knowledge with emerging physician/scientists who will add to the body of knowledge in medicine—enriching one patient at a time and society as a whole.

If we work together, we can assure the continuation of our medical heritage for Colorado and beyond and the many practices that provide state-of-the-art patient care.
The Promise of Young Fellows

Veteran cancer researcher and clinician William Robinson, MD, mentors talented young oncologists like Peter Kabos, MD.

The Hematology/Oncology Fellowship Program has reached an important milestone. A little more than 30 years ago, William Robinson, MD, became head of the new Division of Medical Oncology, ushering in an era of excellence in training at the University of Colorado Denver.

Over the years, senior faculty members like Robinson have trained hundreds of young specialists like Peter Kabos, MD, a fellow in medical oncology who was recently awarded the prestigious young investigator award from the American Society of Clinical Oncologists (ASCO). Kabos and his research team, led by Kate Horwitz, PhD, recently reported important new breast cancer findings in the journal *Proceedings of the National Academy of Sciences*. They found that breast cancer progenitor cells lack hormone receptors. These stem-like cells may survive hormone therapy and trigger regrowth of new hormone-resistant tumors. Also, they reported it is possible that women taking estrogen plus progestin hormone replacement therapy may be at higher risk for breast cancer than women taking only estrogens because the combination therapy reactivates small, undiagnosed, possibly dormant breast cancers.

“Peter is certainly one of the best and the brightest. Our fellowship program brought him here from across the world, and once he finishes the program, we will keep him on as Assistant Professor in the Division of Medical Oncology. I couldn’t be more pleased,” said Robinson.

To learn about the many ways you can make a gift:

**Contact**

**Camy Cooney, CFRE**
Senior Director of Development
University of Colorado Foundation
Anschutz Medical Campus
P.O. Box 6508
Mail Stop F-434
Aurora, CO 80045-0511
Phone: 303-724-4131
Cell: 303-909-6190
Fax: 303-724-3048
camy.cooney@cufund.org

[www.cufund.org](http://www.cufund.org)